The global Pharmaceutical Formulation Development market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Pharmaceutical formulation development is the process of designing and developing a dosage form or drug product that contains the active pharmaceutical ingredient (API) in a suitable form for administration to patients. It involves the selection of appropriate excipients, development of a stable and effective formulation, and optimization of the manufacturing process.
The goal of formulation development is to ensure that the drug product is safe, effective, and of high quality. It involves various stages, including pre-formulation studies, formulation design, process development, and optimization. The formulation development team works closely with other departments, such as analytical development, regulatory affairs, and manufacturing, to ensure that the final product meets all the necessary requirements.
During the formulation development process, factors such as the physicochemical properties of the API, desired route of administration, patient population, and stability considerations are taken into account. Different dosage forms, such as tablets, capsules, liquids, creams, and injectables, may be developed depending on the specific requirements of the drug.
Formulation development also involves conducting stability studies to assess the shelf-life of the drug product under various storage conditions. This helps to ensure that the formulation remains stable and retains its potency and quality throughout its intended shelf-life.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Pharmaceutical Formulation Development market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pharmaceutical Formulation Development market size and forecasts, in consumption value ($ Million), 2020-2031
Global Pharmaceutical Formulation Development market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Pharmaceutical Formulation Development market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Pharmaceutical Formulation Development market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pharmaceutical Formulation Development
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pharmaceutical Formulation Development market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include LGM Pharma, Dalton Pharma Services, Recipharm, Aurigene Pharmaceutical Services, Coriolis Pharma, Intertek, Quay Pharma, Lonza, Ardena, Kemwell, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Pharmaceutical Formulation Development market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Oral
External Use
麻豆原创 segment by Application
Hospital
Enterprise
麻豆原创 segment by players, this report covers
LGM Pharma
Dalton Pharma Services
Recipharm
Aurigene Pharmaceutical Services
Coriolis Pharma
Intertek
Quay Pharma
Lonza
Ardena
Kemwell
SGS
Syngene International
Piramal Pharma Solutions
Pharma Mo Ltd
Metrics Contract Services
COREALIS Pharma
Element Materials Technology
Adare Pharma Solutions
Singota Solutions
Creative Biolabs
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pharmaceutical Formulation Development product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pharmaceutical Formulation Development, with revenue, gross margin, and global market share of Pharmaceutical Formulation Development from 2020 to 2025.
Chapter 3, the Pharmaceutical Formulation Development competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Pharmaceutical Formulation Development market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmaceutical Formulation Development.
Chapter 13, to describe Pharmaceutical Formulation Development research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Pharmaceutical Formulation Development by Type
1.3.1 Overview: Global Pharmaceutical Formulation Development 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Pharmaceutical Formulation Development Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Oral
1.3.4 External Use
1.4 Global Pharmaceutical Formulation Development 麻豆原创 by Application
1.4.1 Overview: Global Pharmaceutical Formulation Development 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Enterprise
1.5 Global Pharmaceutical Formulation Development 麻豆原创 Size & Forecast
1.6 Global Pharmaceutical Formulation Development 麻豆原创 Size and Forecast by Region
1.6.1 Global Pharmaceutical Formulation Development 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Pharmaceutical Formulation Development 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Pharmaceutical Formulation Development 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Pharmaceutical Formulation Development 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Pharmaceutical Formulation Development 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Pharmaceutical Formulation Development 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Pharmaceutical Formulation Development 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 LGM Pharma
2.1.1 LGM Pharma Details
2.1.2 LGM Pharma Major Business
2.1.3 LGM Pharma Pharmaceutical Formulation Development Product and Solutions
2.1.4 LGM Pharma Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 LGM Pharma Recent Developments and Future Plans
2.2 Dalton Pharma Services
2.2.1 Dalton Pharma Services Details
2.2.2 Dalton Pharma Services Major Business
2.2.3 Dalton Pharma Services Pharmaceutical Formulation Development Product and Solutions
2.2.4 Dalton Pharma Services Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Dalton Pharma Services Recent Developments and Future Plans
2.3 Recipharm
2.3.1 Recipharm Details
2.3.2 Recipharm Major Business
2.3.3 Recipharm Pharmaceutical Formulation Development Product and Solutions
2.3.4 Recipharm Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Recipharm Recent Developments and Future Plans
2.4 Aurigene Pharmaceutical Services
2.4.1 Aurigene Pharmaceutical Services Details
2.4.2 Aurigene Pharmaceutical Services Major Business
2.4.3 Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Product and Solutions
2.4.4 Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Aurigene Pharmaceutical Services Recent Developments and Future Plans
2.5 Coriolis Pharma
2.5.1 Coriolis Pharma Details
2.5.2 Coriolis Pharma Major Business
2.5.3 Coriolis Pharma Pharmaceutical Formulation Development Product and Solutions
2.5.4 Coriolis Pharma Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Coriolis Pharma Recent Developments and Future Plans
2.6 Intertek
2.6.1 Intertek Details
2.6.2 Intertek Major Business
2.6.3 Intertek Pharmaceutical Formulation Development Product and Solutions
2.6.4 Intertek Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Intertek Recent Developments and Future Plans
2.7 Quay Pharma
2.7.1 Quay Pharma Details
2.7.2 Quay Pharma Major Business
2.7.3 Quay Pharma Pharmaceutical Formulation Development Product and Solutions
2.7.4 Quay Pharma Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Quay Pharma Recent Developments and Future Plans
2.8 Lonza
2.8.1 Lonza Details
2.8.2 Lonza Major Business
2.8.3 Lonza Pharmaceutical Formulation Development Product and Solutions
2.8.4 Lonza Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Lonza Recent Developments and Future Plans
2.9 Ardena
2.9.1 Ardena Details
2.9.2 Ardena Major Business
2.9.3 Ardena Pharmaceutical Formulation Development Product and Solutions
2.9.4 Ardena Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Ardena Recent Developments and Future Plans
2.10 Kemwell
2.10.1 Kemwell Details
2.10.2 Kemwell Major Business
2.10.3 Kemwell Pharmaceutical Formulation Development Product and Solutions
2.10.4 Kemwell Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Kemwell Recent Developments and Future Plans
2.11 SGS
2.11.1 SGS Details
2.11.2 SGS Major Business
2.11.3 SGS Pharmaceutical Formulation Development Product and Solutions
2.11.4 SGS Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 SGS Recent Developments and Future Plans
2.12 Syngene International
2.12.1 Syngene International Details
2.12.2 Syngene International Major Business
2.12.3 Syngene International Pharmaceutical Formulation Development Product and Solutions
2.12.4 Syngene International Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Syngene International Recent Developments and Future Plans
2.13 Piramal Pharma Solutions
2.13.1 Piramal Pharma Solutions Details
2.13.2 Piramal Pharma Solutions Major Business
2.13.3 Piramal Pharma Solutions Pharmaceutical Formulation Development Product and Solutions
2.13.4 Piramal Pharma Solutions Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Piramal Pharma Solutions Recent Developments and Future Plans
2.14 Pharma Mo Ltd
2.14.1 Pharma Mo Ltd Details
2.14.2 Pharma Mo Ltd Major Business
2.14.3 Pharma Mo Ltd Pharmaceutical Formulation Development Product and Solutions
2.14.4 Pharma Mo Ltd Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Pharma Mo Ltd Recent Developments and Future Plans
2.15 Metrics Contract Services
2.15.1 Metrics Contract Services Details
2.15.2 Metrics Contract Services Major Business
2.15.3 Metrics Contract Services Pharmaceutical Formulation Development Product and Solutions
2.15.4 Metrics Contract Services Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Metrics Contract Services Recent Developments and Future Plans
2.16 COREALIS Pharma
2.16.1 COREALIS Pharma Details
2.16.2 COREALIS Pharma Major Business
2.16.3 COREALIS Pharma Pharmaceutical Formulation Development Product and Solutions
2.16.4 COREALIS Pharma Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 COREALIS Pharma Recent Developments and Future Plans
2.17 Element Materials Technology
2.17.1 Element Materials Technology Details
2.17.2 Element Materials Technology Major Business
2.17.3 Element Materials Technology Pharmaceutical Formulation Development Product and Solutions
2.17.4 Element Materials Technology Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Element Materials Technology Recent Developments and Future Plans
2.18 Adare Pharma Solutions
2.18.1 Adare Pharma Solutions Details
2.18.2 Adare Pharma Solutions Major Business
2.18.3 Adare Pharma Solutions Pharmaceutical Formulation Development Product and Solutions
2.18.4 Adare Pharma Solutions Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Adare Pharma Solutions Recent Developments and Future Plans
2.19 Singota Solutions
2.19.1 Singota Solutions Details
2.19.2 Singota Solutions Major Business
2.19.3 Singota Solutions Pharmaceutical Formulation Development Product and Solutions
2.19.4 Singota Solutions Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 Singota Solutions Recent Developments and Future Plans
2.20 Creative Biolabs
2.20.1 Creative Biolabs Details
2.20.2 Creative Biolabs Major Business
2.20.3 Creative Biolabs Pharmaceutical Formulation Development Product and Solutions
2.20.4 Creative Biolabs Pharmaceutical Formulation Development Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Creative Biolabs Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Pharmaceutical Formulation Development Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Pharmaceutical Formulation Development by Company Revenue
3.2.2 Top 3 Pharmaceutical Formulation Development Players 麻豆原创 Share in 2024
3.2.3 Top 6 Pharmaceutical Formulation Development Players 麻豆原创 Share in 2024
3.3 Pharmaceutical Formulation Development 麻豆原创: Overall Company Footprint Analysis
3.3.1 Pharmaceutical Formulation Development 麻豆原创: Region Footprint
3.3.2 Pharmaceutical Formulation Development 麻豆原创: Company Product Type Footprint
3.3.3 Pharmaceutical Formulation Development 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Pharmaceutical Formulation Development Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Pharmaceutical Formulation Development 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Pharmaceutical Formulation Development Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Pharmaceutical Formulation Development 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical Formulation Development Consumption Value by Type (2020-2031)
6.2 North America Pharmaceutical Formulation Development 麻豆原创 Size by Application (2020-2031)
6.3 North America Pharmaceutical Formulation Development 麻豆原创 Size by Country
6.3.1 North America Pharmaceutical Formulation Development Consumption Value by Country (2020-2031)
6.3.2 United States Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Pharmaceutical Formulation Development Consumption Value by Type (2020-2031)
7.2 Europe Pharmaceutical Formulation Development Consumption Value by Application (2020-2031)
7.3 Europe Pharmaceutical Formulation Development 麻豆原创 Size by Country
7.3.1 Europe Pharmaceutical Formulation Development Consumption Value by Country (2020-2031)
7.3.2 Germany Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical Formulation Development Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Pharmaceutical Formulation Development Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Pharmaceutical Formulation Development 麻豆原创 Size by Region
8.3.1 Asia-Pacific Pharmaceutical Formulation Development Consumption Value by Region (2020-2031)
8.3.2 China Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Pharmaceutical Formulation Development Consumption Value by Type (2020-2031)
9.2 South America Pharmaceutical Formulation Development Consumption Value by Application (2020-2031)
9.3 South America Pharmaceutical Formulation Development 麻豆原创 Size by Country
9.3.1 South America Pharmaceutical Formulation Development Consumption Value by Country (2020-2031)
9.3.2 Brazil Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical Formulation Development Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Pharmaceutical Formulation Development Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Pharmaceutical Formulation Development 麻豆原创 Size by Country
10.3.1 Middle East & Africa Pharmaceutical Formulation Development Consumption Value by Country (2020-2031)
10.3.2 Turkey Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Pharmaceutical Formulation Development 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Pharmaceutical Formulation Development 麻豆原创 Drivers
11.2 Pharmaceutical Formulation Development 麻豆原创 Restraints
11.3 Pharmaceutical Formulation Development Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Pharmaceutical Formulation Development Industry Chain
12.2 Pharmaceutical Formulation Development Upstream Analysis
12.3 Pharmaceutical Formulation Development Midstream Analysis
12.4 Pharmaceutical Formulation Development Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LGM Pharma
Dalton Pharma Services
Recipharm
Aurigene Pharmaceutical Services
Coriolis Pharma
Intertek
Quay Pharma
Lonza
Ardena
Kemwell
SGS
Syngene International
Piramal Pharma Solutions
Pharma Mo Ltd
Metrics Contract Services
COREALIS Pharma
Element Materials Technology
Adare Pharma Solutions
Singota Solutions
Creative Biolabs
听
听
*If Applicable.
